AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20119647 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 PTX3 levels correlation with clinical parameters.
Number of subjects: 90
Study 20119647 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 PTX3 levels correlation with coagulation markers.
Number of subjects: 90
Study 18559700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS (gastrointestinal therapeutic system)
Number of subjects: 10069
Study 16053952 — intervention group
Group type: COMPARATOR
Intervention: TNK alone
Number of subjects: 170
Study 16053952 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-facilitated angioplasty
Number of subjects: 170
Study 11994055 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (3.2 mg kg‐1 on day 0 and 1.6 mg kg‐1 on days 1‐4)
Number of subjects: 22
Study 11994055 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (3.2 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Number of subjects: 22
Study 11994055 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment R (artemether: 3.2 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Number of subjects: 22
Study 11994055 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (1.6 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Number of subjects: 22
Study 11994055 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C
Number of subjects: 22
Study 11994055 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment R
Number of subjects: 22
Study 10424739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan with high-fat breakfast
Number of subjects: 18
Study 10424739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan without food
Number of subjects: 18
Study 10424739 — intervention group
Group type: COMPARATOR
Intervention: Intravenous topotecan
Number of subjects: 18
Study 10424739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (fasted)
Number of subjects: 18
Study 7844666 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP vaccine after first dose
Number of subjects: 300
Study 7844666 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine after two doses
Number of subjects: 300
Study 7844666 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine after three doses
Number of subjects: 300
Study 7844666 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP followed by HbOC or PRP-T
Number of subjects: 300
Study 2090783 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter grading system
Number of subjects: 19
Study 2090783 — intervention group
Group type: COMPARATOR
Intervention: Pass-fail grading system
Number of subjects: 19
Study 30132370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequentially monitored clinical trials that did not stop early for benefit
Number of subjects: 0
Study 30132370 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional approach to estimation
Number of subjects: 0
Study 30132370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias-adjusted estimate
Number of subjects: 0
Study 29018021 — intervention group
Group type: EXPERIMENTAL
Intervention: <6 hours sleep per night
Number of subjects: 13026
Study 29018021 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screening for obstructive sleep apnea
Number of subjects: 13026
Study 29018021 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight shift work (≥3 night shifts/week for ≥1 year)
Number of subjects: 13026
Study 29018021 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of all 3 sleep-related risk factors
Number of subjects: 13026
Study 25926370 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold IMT (TG)
Number of subjects: 40
Study 25926370 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (ISG)
Number of subjects: 40
Study 25926370 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 23168455 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 44
Study 23168455 — intervention group
Group type: COMPARATOR
Intervention: Postal questionnaire
Number of subjects: 44
Study 21610487 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT invitations for male sexual partners (MSPs)
Number of subjects: 1000
Study 21610487 — intervention group
Group type: COMPARATOR
Intervention: PIS invitations for MSPs
Number of subjects: 1000
Study 21610487 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT arm for MSPs
Number of subjects: 1000
Study 21610487 — intervention group
Group type: COMPARATOR
Intervention: PIS arm for MSPs
Number of subjects: 1000
Study 21610487 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT arm for MSPs regarding unprotected sex
Number of subjects: 1000
Study 21610487 — intervention group
Group type: COMPARATOR
Intervention: PIS arm for MSPs regarding unprotected sex
Number of subjects: 1000
Study 21610487 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT arm for women regarding unprotected sex
Number of subjects: 1000
Study 21610487 — intervention group
Group type: COMPARATOR
Intervention: PIS arm for women regarding unprotected sex
Number of subjects: 1000
Study 18007263 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral supplement (500 mL of Intestamin, Fresenius Kabi) containing conditionally essential nutrients
Number of subjects: 55
Study 18007263 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition formula (experimental group)
Number of subjects: 55
Study 18007263 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control group)
Number of subjects: 55
Study 18007263 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral supplement
Number of subjects: 55
Study 16420512 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Number of subjects: 60
Study 16420512 — intervention group
Group type: COMPARATOR
Intervention: 24-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Number of subjects: 60
Study 16420512 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week peginterferon-alpha-2b plus ribavirin in patients with unfavorable predictors
Number of subjects: 60
Study 16420512 — intervention group
Group type: COMPARATOR
Intervention: 24-week peginterferon-alpha-2b plus ribavirin in patients with unfavorable predictors
Number of subjects: 60
Study 16420512 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week peginterferon-alpha-2b plus ribavirin
Number of subjects: 60
Study 16420512 — intervention group
Group type: COMPARATOR
Intervention: 24-week peginterferon-alpha-2b plus ribavirin
Number of subjects: 60
Study 12830603 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter plus titrated oral misoprostol solution
Number of subjects: 526
Study 12830603 — intervention group
Group type: COMPARATOR
Intervention: Titrated oral misoprostol solution alone
Number of subjects: 526
Study 12830603 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 526
Study 11138880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicillin CR with procaine
Number of subjects: 50
Study 11138880 — intervention group
Group type: COMPARATOR
Intervention: Bicillin LA
Number of subjects: 50
Study 9192924 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme (Experimental group)
Number of subjects: 312
Study 9192924 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Airways programme (Experimental group)
Number of subjects: 312
Study 9192924 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened educational programme (4 weeks)
Number of subjects: 312
Study 9192924 — intervention group
Group type: COMPARATOR
Intervention: Standard care without education (Comparison group)
Number of subjects: 312
Study 1486157 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release indomethacin (Eudragit L formulation)
Number of subjects: 45
Study 1486157 — intervention group
Group type: COMPARATOR
Intervention: Standard indomethacin
Number of subjects: 45
Study 4033403 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3 d/wk, 8-wk aerobics program at 70-85% maximum heart rate)
Number of subjects: 72
Study 4033403 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (NE)
Number of subjects: 72
Study 29781921 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIN group (16-week high-intensity interval training)
Number of subjects: 55
Study 29781921 — intervention group
Group type: COMPARATOR
Intervention: CONT group (non-exercising)
Number of subjects: 55
Study 27731828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium 50 mg test (F4) tablet formulation
Number of subjects: 12
Study 27731828 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Caflam)
Number of subjects: 12
Study 24815497 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (nonselective COX inhibitor)
Number of subjects: 12
Study 24815497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24815497 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrex (selective COX-2 inhibitor)
Number of subjects: 12
Study 22141461 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation mode showing wayfinding information from eye-level
Number of subjects: 132
Study 22141461 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation modes showing wayfinding information included in views providing comprehensive configural information
Number of subjects: 132
Study 22141461 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation mode which always showed north on top of the device
Number of subjects: 132
Study 22141461 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation mode which rotated according to the orientation of the user
Number of subjects: 132
Study 22141461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both presentation modes based on map fragments
Number of subjects: 132
Study 22141461 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences in visual-spatial working memory capacity
Number of subjects: 132
Study 20605301 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate quartile 1
Number of subjects: 839
Study 20605301 — intervention group
Group type: COMPARATOR
Intervention: Serum bicarbonate quartile 4
Number of subjects: 839
Study 19197198 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased resistance in the squat exercise
Number of subjects: 10
Study 19197198 — intervention group
Group type: COMPARATOR
Intervention: No increase in resistance in the squat exercise
Number of subjects: 10
Study 16170936 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified flicker technique with 5 or 8 seconds time constraints
Number of subjects: 62
Study 12241713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow‐mononuclear cells
Number of subjects: 45
Study 12241713 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood‐mononuclear cells
Number of subjects: 45
Study 10403615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sinitrodil
Number of subjects: 0
Study 10403615 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sinitrodil
Number of subjects: 0
Study 10403615 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg sinitrodil
Number of subjects: 0
Study 10403615 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study 10403615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7636779 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (state anxiety, avoidance coping, anger held in)
Number of subjects: 186
Study 1851709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 70
Study 1851709 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 70
Study 7016628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free soy isolate formula (Isomil)
Number of subjects: 112
Study 7016628 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk-based formula
Number of subjects: 112
Study 31570246 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation therapy (CRT)
Number of subjects: 4347
Study 31570246 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy alone
Number of subjects: 4347
Study 31570246 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CRT
Number of subjects: 4347
Study 31226443 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth, individualized RT plan review during week 1 of RT (Arm B)
Number of subjects: 64
Study 31226443 — intervention group
Group type: COMPARATOR
Intervention: Standard nondetailed review (Arm A)
Number of subjects: 64
Study 28506550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐ and postoperative sevoflurane (SS)
Number of subjects: 90
Study 28506550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative sevoflurane and postoperative propofol (SP)
Number of subjects: 90
Study 28506550 — intervention group
Group type: COMPARATOR
Intervention: Intra‐ and postoperative propofol (PP)
Number of subjects: 90
Study 25856039 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-led BSE education with additional written BSE instructions
Number of subjects: 37
Study 25856039 — intervention group
Group type: COMPARATOR
Intervention: CNS-led BSE education without additional written BSE instructions
Number of subjects: 37
Study 23968769 — intervention group
Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10³ PFU
Number of subjects: 0
Study 23968769 — intervention group
Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10⁴ PFU
Number of subjects: 0
Study 23968769 — intervention group
Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10⁵ PFU
Number of subjects: 0
Study 23968769 — intervention group
Group type: EXPERIMENTAL
Intervention: rWN/DEN4Δ30 vaccine at 10⁵ PFU (second dose)
Number of subjects: 0
Study 22068922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 1050
Study 22068922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (17.4 mg/24 h)
Number of subjects: 1050
Study 22068922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsule (12 mg/day)
Number of subjects: 1050
Study 22068922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 19916253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US)
Number of subjects: 83
Study 15668708 — intervention group
Group type: EXPERIMENTAL
Intervention: A ‐‐> CMF
Number of subjects: 466
Study 15668708 — intervention group
Group type: EXPERIMENTAL
Intervention: GT after chemotherapy
Number of subjects: 466
Study 15668708 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 466
Study 15668708 — intervention group
Group type: COMPARATOR
Intervention: CMF followed by GT
Number of subjects: 466
Study 11805748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 28
Study 11805748 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 28
Study 10076616 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibrin glue (HFG) used during hernia repair (group A)
Number of subjects: 50
Study 10076616 — intervention group
Group type: COMPARATOR
Intervention: Control group without HFG (group B)
Number of subjects: 50
Study 8750368 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous lamivudine (administered over 1 hour)
Number of subjects: 12
Study 8750368 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral lamivudine (1 mg/mL)
Number of subjects: 12
Study 8750368 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg capsule
Number of subjects: 12
Study 8750368 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tablet
Number of subjects: 12
Study 8750368 — intervention group
Group type: COMPARATOR
Intervention: All oral formulations (oral solution, capsule, tablet)
Number of subjects: 12
Study 2040325 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 193
Study 2040325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 7034454 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 19
Study 7034454 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 3%
Number of subjects: 19
Study 31715272 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 582
Study 31715272 — intervention group
Group type: COMPARATOR
Intervention: Urine culture
Number of subjects: 582
Study 30274727 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE intervention lessons taught by paraprofessional educators
Number of subjects: 312
Study 30274727 — intervention group
Group type: COMPARATOR
Intervention: Nutrition curriculum delivered by classroom teachers
Number of subjects: 312
Study 27935458 — intervention group
Group type: EXPERIMENTAL
Intervention: Group session of hypnosis with a hypnotic induction (n = 84)
Number of subjects: 167
Study 27935458 — intervention group
Group type: COMPARATOR
Intervention: No-induction group receiving identical suggestions without a hypnotic induction (n = 83)
Number of subjects: 167
Study 25975632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bev+D‐FEC
Number of subjects: 800
Study 25975632 — intervention group
Group type: COMPARATOR
Intervention: D‐FEC
Number of subjects: 800
Study 23359433 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO)
Number of subjects: 0
Study 20012308 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily for 6 months
Number of subjects: 85
Study 18762289 — intervention group
Group type: EXPERIMENTAL
Intervention: Global property resemblance
Number of subjects: 0
Study 18762289 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier representing global properties
Number of subjects: 0
Study 18762289 — intervention group
Group type: COMPARATOR
Intervention: Models representing scene object information
Number of subjects: 0
Study 17531764 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 VLP AS04 vaccine administered at months 0, 1, and 6
Number of subjects: 773
Study 17531764 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 VLP AS04 vaccine
Number of subjects: 773
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/drospirenone)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/cyproterone)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/desogestrel)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/gestodene)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/chlormadinone)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/levonorgestrel)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/norethindrone)
Number of subjects: 0
Study 15663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (ethinylestradiol/norgestimate)
Number of subjects: 0
Study 15663340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11680569 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (rabbit anti‐thymocyte globulin), 1.5 mg/kg/day for 6‐14 days
Number of subjects: 79
Study 11680569 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (rabbit anti‐thymocyte globulin)
Number of subjects: 79
Study 9477711 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated Standards for Preparation of Controlled Clinical Trials (CONSORT) checklist
Number of subjects: 0
Study 9477711 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi process
Number of subjects: 0
Study 7861706 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic higher sodium intake
Number of subjects: 21
Study 7861706 — intervention group
Group type: EXPERIMENTAL
Intervention: Before angiotensin infusion
Number of subjects: 21
Study 7861706 — intervention group
Group type: EXPERIMENTAL
Intervention: During angiotensin infusion
Number of subjects: 21
Study 2910264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental effort to increase right patellar reflex
Number of subjects: 48
Study 2910264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental effort to increase right patellar reflex and decrease left
Number of subjects: 48
Study 2910264 — intervention group
Group type: COMPARATOR
Intervention: Mental effort to increase either right or left knee jerk
Number of subjects: 48
Study 45587 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine 200 mg
Number of subjects: 72
Study 45587 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine 60 mg
Number of subjects: 72
Study 31940670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Safety Dashboard
Number of subjects: 12
Study 31756207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic Reading Group (DRG, n = 16)
Number of subjects: 32
Study 31756207 — intervention group
Group type: COMPARATOR
Intervention: Screen Story Group (SSG, n = 16)
Number of subjects: 32
Study 28231290 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive sensory evaluation of apple cultivars
Number of subjects: 85
Study 26178501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (stable blood glucose at 6.1‐8.3 mmol/L)
Number of subjects: 72
Study 23201367 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong placebo treatment
Number of subjects: 0
Study 23201367 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak placebo treatment
Number of subjects: 0
Study 23201367 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatments (both strong and weak)
Number of subjects: 0
Study 21694454 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17‐β estradiol (unopposed and opposed with medroxyprogesterone) for 12 months
Number of subjects: 43
Study 21694454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 43
Study 18435322 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric 'skills and drills' training
Number of subjects: 0
Study 16148997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cancer group (MCG)
Number of subjects: 1125